A new study by Owlstone Medical and underpinned by research by the University of Birmingham has successfully demonstrated the use of exhaled limonene as a breath-biomarker to measure liver function and disease.
The positive results of the study, published today in Clinical and Translational Gastroenterology, validate Owlstone Medical’s EVOC® probe strategy for the development of breath-based diagnostic and prognostic tests for Non-alcoholic Fatty Liver Disease (NAFLD) and associated Non-alcoholic steatohepatitis (NASH).
In the study, exhaled breath from 32 cirrhosis patients and 12 cirrhotic hepatocellular-carcinoma patients was compared with 40 controls. Breath samples were analyzed by Owlstone Medical’s Breath Biopsy platform. The results (sensitivity of 73%, specificity of 77%) clearly demonstrated that limonene levels are associated with alterations in liver function. Limonene therefore holds great promise as a marker of liver metabolic capacity, particularly when considering that the study results reflected only normal dietary intake of limonene as a single biomarker rather than being deployed as an optimized EVOC probe, which can be expected to yield far better performance.
Breath is an area that holds great potential. Studies have suggested that metabolic dysfunction in liver disease is reflected in the composition of exhaled breath, with limonene, a naturally occurring chemical that is found in citrus foods, being particularly promising. Limonene was identified as a biomarker for liver disease in a paper by Professor Mayhew, Owlstone Medical Scientific Advisory Board member, and his research team at the University of Birmingham in 2015. Key to the work led by Professor Mayhew is that pre and post-liver transplant breath samples were investigated, which unambiguously allowed the researchers to assign limonene as a distinct biomarker for liver disease.
Driven by the global epidemics of obesity and diabetes, NAFLD/NASH is becoming increasingly common with a worldwide prevalence estimated at 25% for NAFLD, and with many of these cases (1.5–6.45% global incidence) progressing to NASH. This is placing a significant and growing demand on healthcare systems globally. In the United States, estimated annual direct medical and societal costs for NASH and NAFLD amount to $292B per year and in Europe total approximately €235B per year. The key to preventing deaths and reducing the economic impact of liver disease is earlier detection and intervention. Unfortunately however, 75% of diagnoses occur at late stage due to a lack of suitable and specific diagnostic tools that can be deployed in a screening setting.
Owlstone Medical is currently developing non-invasive quantitative breath tests that will use EVOC Probes, including limonene, a GRAS (Generally Recognized as Safe) compound, along with inflammatory exhaled biomarkers, to measure liver enzyme activity and provide information on the health of the liver and for NAFLD/NASH diagnosis and prognosis. These tests will initially be offered in research settings including to pharma companies developing NAFLD/NASH drugs, with launch as clinical tests to follow.
Dr Chris Mayhew, Professor of Molecular Physics at the University of Birmingham and Director of the Institute for Breath Research at the University of Innsbruck in Austria, commented: “The results from this study and its implications for liver disease diagnostics are very promising.
“When a probe with higher levels of limonene optimized for this application is used, along with other markers to measure liver function, the potential for this approach to non-invasively stage liver disease and to measure the progression or recovery from disease is excellent.”
Dr Victoria Snowdon, Consultant, Transplant Hepatology, Cambridge University Hospitals, noted: “The burden of liver disease is high and continues to grow, and so assessment of liver function is essential for determining prognosis and establishing effective treatment. The findings of this study suggest that a breath test could non-invasively help us determine liver function, helping to monitor patients with liver disease from an early stage and optimize treatment.
“We are pleased to have contributed to these findings through the PAN study and would like to thank all our patients at Addenbrooke’s who took part. Without their help we would be unable to develop new and improved ways of diagnosing and treating disease.”
Billy Boyle, co-founder and CEO at Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, said: “This study represents a major milestone for Owlstone Medical, as it is the first proof of the value of our EVOC probe approach for the development of breath tests in areas of high clinical need. Much like how PET scans work, this involves the introduction of a compound to the body that elicits a strong and clearly readable signal over background.
“We have identified a number of additional highly promising compounds that we are working to validate as EVOC probes for liver disease and we believe our EVOC probe approach can be applied to other disease areas, including lung cancer, where earlier and improved diagnosis is clearly needed to save lives.”
The study operated as part of Owlstone Medical’s PAN study. Patients were recruited from the clinical research facility at Cambridge University Hospitals or through the Cambridge BioResource. Cirrhotic hepatocellular-carcinoma patients had an established diagnosis prior to entry into the study.